Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth Novartis secures development and commercialization rights in North America, Europe, and Japan Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcin...